JPRN-UMIN000002846已完成2 期
Phase II study of pematrexed plus carboplatin in previously untreated non-small cell, non-squamous cell lung cancer - Phase II trial of PEM/CBDCA for NSCLC
Hokkaido Lung Cancer Study Group0 个研究点目标入组 40 人开始时间: 2009年12月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Active infection 2) fever >= 38C 3) Severe and uncontrolled complication 4) Other active malignancies 5) Unstable metastases to the brain 6) Uncontrolled pleural, pericardial effusion or ascites 7) Presence of active interstitial pneumonia 8) Allergy to treatment drugs 9) Pregnant patients 10) Unstable psychic disorder 11) Continuous use of steroid 12) Decision of ineligibility by a physician
研究者
相似试验
已完成
2 期
Phase II study of carboplatin and pemetrexed plus bevacizumab after failure of first-line EGFR TKI therapy for non-small-cell lung cancer harboring EGFR mutation.on-squamous Non-small-cell Lung CancerJPRN-UMIN000004731Central Japan Lung Study Group27
招募中
1 期
A Phase 2 study of Carboplatin plus Pemetrexed plus Bevacizumab as first-line therapy for stage3B/4 non-squamous non-small-cell lung cancerung CancerJPRN-UMIN000005143Dokkyo Medical University30
招募中
2 期
A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancer (EGFR mutation status Negative)JPRN-UMIN000005991Toho University Omori Medical Center35
已完成
2 期
A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed Plus Bevacizumab in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancerJPRN-UMIN000003770Osaka Lung Cancer Study Group40
已完成
2 期
A Phase II study of Pemetrexed plus Carboplatin followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancerJPRN-UMIN000003755Dept. of Respiratory Medicine, Osaka University Hospital40